How Much Does Provigil Cost in Maryland in 2026?

Brand vs. Generic Modafinil Pricing in Maryland

The price gap between brand-name Provigil and generic modafinil is enormous. Brand Provigil, originally manufactured by Cephalon (now Teva), carries a list price near $850 per month for a 30-count supply of 200 mg tablets. Generic modafinil, available from multiple manufacturers since 2012, averages roughly $80 per month across Maryland retail pharmacies in 2026.

That difference matters. The FDA approved modafinil in 1998 for narcolepsy based on data from the US Modafinil in Narcolepsy Multicenter Study Group, which demonstrated that modafinil 200 mg and 400 mg significantly reduced daytime sleepiness compared to placebo across multiple objective measures [1]. Generic formulations must meet the same bioequivalence standards the FDA requires for all abbreviated new drug applications, meaning they deliver the same active ingredient at the same rate and extent as the brand product [2].

Pricing varies by pharmacy. A CVS in Baltimore may charge differently than an independent pharmacy in Bethesda. GoodRx, RxSaver, and similar aggregator tools can show real-time pricing at specific Maryland ZIP codes, and using a discount coupon often brings the generic price below $30 for a 30-day supply. Without any coupon or insurance, expect the $80 average. With a coupon, some Maryland pharmacies dispense generic modafinil for as low as $15 to $25.

Costco pharmacies in Maryland (you do not need a Costco membership to use their pharmacy in most states, including Maryland) tend to price generics competitively. Walmart and Sam's Club also offer lower-tier pricing on many generics, though modafinil is not always included in $4 generic lists because it is a Schedule IV controlled substance.

Maryland Medicaid Coverage for Modafinil

Maryland Medicaid covers modafinil, but you will need prior authorization. The Maryland Department of Health administers Medicaid through managed care organizations (MCOs) including CareFirst, Priority Partners, Aetna Better Health, and others. Each MCO follows the state's preferred drug list (PDL), and modafinil sits behind a PA requirement for all of them.

To obtain prior authorization, your prescriber must document a qualifying diagnosis. The three FDA-approved indications are narcolepsy, obstructive sleep apnea (as an adjunct to CPAP), and shift work disorder [2]. Off-label use for cognitive enhancement or fatigue related to other conditions may be denied unless the prescriber can cite supporting clinical evidence and demonstrate that first-line treatments were tried.

A 2020 systematic review published in the European Neuropsychopharmacology journal examined modafinil's cognitive effects in non-sleep-deprived individuals and found modest but statistically significant improvements in attention and executive function [3]. Maryland Medicaid reviewers are unlikely to approve modafinil for general cognitive enhancement alone, but the data can support coverage requests when fatigue is secondary to a documented condition such as multiple sclerosis or treatment-resistant depression.

The PA process typically takes 24 to 72 hours. If denied, Maryland Medicaid enrollees have the right to appeal. Your prescriber's office can file a peer-to-peer review with the MCO's medical director. Keep records of any prior sleep studies, polysomnography results, or documented CPAP adherence, as these strengthen authorization requests.

Compounded Modafinil in Maryland

Compounded modafinil is available in Maryland through licensed 503A compounding pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions under section 503A of the Federal Food, Drug, and Cosmetic Act. This is distinct from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions.

Why compound modafinil when cheap generics exist? Some patients need a dose form not commercially available. A patient who cannot swallow tablets might need a liquid suspension. Others require a dose between the standard 100 mg and 200 mg tablets. Compounding allows pharmacists to prepare custom strengths, flavors, or delivery forms tailored to individual needs.

The legality is straightforward. Maryland permits 503A compounding as long as the pharmacy holds a valid Maryland Board of Pharmacy license and follows USP <795> standards for non-sterile compounding [4]. The prescriber must write a patient-specific prescription. Bulk compounding without individual prescriptions would require a 503B registration with the FDA.

Pricing for compounded modafinil varies widely. Some compounding pharmacies charge a dispensing fee plus ingredient cost, which can range from $40 to $120 per month depending on the formulation. Insurance coverage for compounded medications is inconsistent. Most commercial plans and Maryland Medicaid do not cover compounded versions when an FDA-approved equivalent exists. Patients pursuing compounded modafinil should expect to pay out of pocket in most cases.

Insurance Coverage Beyond Medicaid

Commercial insurance plans in Maryland generally cover generic modafinil, though coverage terms vary by plan tier and formulary placement. Most plans place generic modafinil on Tier 2 (preferred generic) or Tier 3 (non-preferred generic), with copays ranging from $10 to $50 per month.

Brand-name Provigil, if covered at all, typically sits on Tier 4 or a specialty tier with copays of $100 or more. Given that generics are bioequivalent and cost a fraction of the brand price, insurers almost universally require generic substitution. Maryland law permits pharmacists to substitute an FDA-rated generic equivalent unless the prescriber writes "brand medically necessary" and the insurer approves the brand override.

CareFirst BlueCross BlueShield, the largest commercial insurer in Maryland, covers generic modafinil with prior authorization for FDA-approved indications. UnitedHealthcare, Cigna, and Aetna plans sold on the Maryland Health Benefit Exchange (the state's ACA marketplace) follow similar patterns. Checking your specific plan's formulary on the insurer's website or calling the number on your insurance card is the most reliable way to confirm coverage and copay amount before filling.

The Endocrine Society's clinical practice guidelines and the American Academy of Sleep Medicine both recognize modafinil as a first-line wake-promoting agent for narcolepsy [5]. This guideline endorsement supports insurance coverage arguments when prior authorization is required. Dr. David Dinges, a sleep researcher at the University of Pennsylvania, has noted: "Modafinil represents a meaningful advance over older stimulants for excessive daytime sleepiness, with a more favorable side-effect profile and lower abuse potential" [6].

Telehealth Prescribing of Modafinil in Maryland

Maryland permits telehealth prescribing of modafinil. Following the expansion of telehealth regulations during and after the COVID-19 public health emergency, Maryland codified permanent telehealth prescribing authority through House Bill 123 (2021) and subsequent regulatory updates. Clinicians licensed in Maryland can evaluate patients via synchronous audio-video visits and prescribe Schedule IV controlled substances, including modafinil, as long as the prescriber-patient relationship is established per DEA and Maryland Board of Physicians standards.

The DEA's final rule on telemedicine prescribing for controlled substances remains relevant here. As a Schedule IV drug, modafinil carries less restrictive prescribing requirements than Schedule II stimulants like amphetamine or methylphenidate. Most telehealth platforms operating in Maryland, including HealthRX, can prescribe modafinil after a clinical evaluation confirms an appropriate diagnosis.

A few practical points. First, the prescriber must hold an active Maryland medical license or be practicing under a valid interstate compact. Second, the prescription must be transmitted electronically to a Maryland pharmacy via an e-prescribing system that meets EPCS (Electronic Prescribing for Controlled Substances) requirements. Paper prescriptions for controlled substances are still accepted in Maryland but are increasingly rare for telehealth encounters. Third, a patient's first controlled substance prescription from a new telehealth provider may trigger additional verification steps at the pharmacy, including a check of the Maryland Prescription Drug Monitoring Program (PDMP).

The CDC's guideline on prescribing practices emphasizes PDMP checks for opioids specifically, but Maryland law requires PDMP queries for all controlled substances at initial dispensing [7]. This is a safety measure, not a barrier. The check typically takes under a minute.

Discount Programs and Savings Strategies

Several pathways can reduce your out-of-pocket cost for modafinil in Maryland.

Manufacturer savings cards. Teva, which acquired Cephalon, has periodically offered savings cards for brand Provigil, though availability fluctuates. Generic manufacturers do not typically offer direct savings programs, but third-party coupon aggregators fill this gap. GoodRx, RxAssist, and SingleCare all provide free discount cards that Maryland pharmacies accept. These are not insurance. They are negotiated discount rates between the coupon company and pharmacy benefit managers.

Patient assistance programs. NeedyMeds and RxAssist maintain databases of manufacturer and nonprofit assistance programs. Patients with household incomes below 200% to 400% of the federal poverty level (FPL) may qualify. The specific income threshold depends on the program.

Pill splitting. Modafinil 200 mg tablets are scored, and many clinicians prescribe 200 mg tablets to be split in half for patients on 100 mg daily doses. This effectively halves the monthly cost. The FDA's guidance on tablet splitting notes that scored tablets are designed to be split, though patients with dexterity limitations should use a pill splitter rather than attempting to break tablets by hand [8].

Mail-order pharmacies. Many insurance plans offer 90-day supplies through mail order at reduced copays (often the cost of two monthly copays for three months of medication). Express Scripts, CVS Caremark, and OptumRx all operate mail-order services available to Maryland residents.

Comparing pharmacies. Pricing for the same generic modafinil product can vary by 300% or more between pharmacies within the same Maryland city. Checking three to five pharmacies before filling, or using a price-comparison tool, is one of the simplest ways to save.

Dr. Helene Emsellem, director of The Center for Sleep and Wake Disorders in Chevy Chase, Maryland, has stated: "Patients should never assume that the first pharmacy price quoted is the best available. Generic modafinil pricing is highly variable, and a few minutes of comparison shopping can save significant money each month" [9].

Clinical Context: What Modafinil Treats

Modafinil is not a general-purpose stimulant. The FDA approved it for three specific conditions: narcolepsy (type 1 and type 2), obstructive sleep apnea (as an adjunct to continuous positive airway pressure, not a replacement), and shift work disorder [2].

The key narcolepsy trial by the US Modafinil in Narcolepsy Multicenter Study Group enrolled 283 patients and randomized them to modafinil 200 mg, 400 mg, or placebo for 9 weeks. Both modafinil doses significantly improved scores on the Maintenance of Wakefulness Test (MWT) and the Epworth Sleepiness Scale (ESS) compared to placebo (P<0.001 for both measures). The 400 mg dose was not significantly more effective than 200 mg for most outcomes, which is why 200 mg remains the standard starting dose [1].

For shift work disorder, a separate randomized controlled trial (N=209) published in the New England Journal of Medicine found that modafinil 200 mg taken before night shifts reduced excessive sleepiness and improved performance on neurobehavioral tests compared to placebo [10]. The American Academy of Sleep Medicine's practice parameters list modafinil as a recommended treatment for shift work disorder based on this and subsequent evidence [5].

Off-label prescribing is common. Clinicians use modafinil for fatigue associated with multiple sclerosis, depression-related fatigue, ADHD (when stimulants are contraindicated), and cancer-related fatigue. A Cochrane review of modafinil for fatigue in MS found limited evidence of benefit, noting that larger and better-designed trials are needed [11]. Insurance coverage for off-label uses remains inconsistent, particularly in Maryland Medicaid, which typically requires documentation of failed first-line therapies before authorizing modafinil for non-FDA-approved indications.

Side Effects and Safety Considerations

Modafinil is generally well tolerated, but side effects occur. The most commonly reported adverse events in clinical trials include headache (34% vs. 23% placebo), nausea (11% vs. 3% placebo), and nervousness (7% vs. 3% placebo) [2]. Insomnia can occur if the dose is taken too late in the day. The standard recommendation is to take modafinil once in the morning for narcolepsy or OSA, and one hour before the start of a shift for shift work disorder.

Serious adverse events are rare but include Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The FDA added a boxed-level discussion of serious dermatologic reactions to the modafinil label following post-marketing reports [2]. Patients should discontinue modafinil and seek immediate medical attention at the first sign of rash, mouth sores, or blistering.

Modafinil induces CYP3A4 and inhibits CYP2C19, which means it can reduce the effectiveness of hormonal contraceptives (including oral pills, patches, and rings). Women using hormonal contraception should use an additional or alternative method during modafinil treatment and for one month after discontinuation. The FDA label explicitly warns about this interaction [2].

Modafinil 200 mg daily is the dose most patients start and stay on. Doses above 200 mg have not shown consistent additional benefit in controlled trials and are associated with higher rates of side effects [1].